Serra V, Eichhorn PJA, GarcÃa-GarcÃa C, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest. 2013;123(6):2551-63. doi:10.1172/JCI66343
Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495-501. doi:10.1038/nature12912
Zhou P, Shaffer DR, Arias DAA, et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature. 2014;506(7486):52-7. doi:10.1038/nature12988
Puissant A, Fenouille N, Alexe G, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014;25(2):226-42. doi:10.1016/j.ccr.2014.01.022
Moody SE, Schinzel AC, Singh S, et al. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene. 2015;34(16):2061-71. doi:10.1038/onc.2014.153
Bar-Nur O, Brumbaugh J, Verheul C, et al. Small molecules facilitate rapid and synchronous iPSC generation. Nat Methods. 2014;11(11):1170-6. doi:10.1038/nmeth.3142
Liu Y, Asnani A, Zou L, et al. Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. Sci Transl Med. 2014;6(266):266ra170. doi:10.1126/scitranslmed.3010189
Ellis CN, LaRocque RC, Uddin T, et al. Comparative proteomic analysis reveals activation of mucosal innate immune signaling pathways during cholera. Infect Immun. 2015;83(3):1089-103. doi:10.1128/IAI.02765-14
Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1-2):48-61. doi:10.1016/j.cell.2014.12.033
Vazquez F, Lim JH, Chim H, et al. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell. 2013;23(3):287-301. doi:10.1016/j.ccr.2012.11.020